Introduction
The protein tau plays ac entral role in ah eterogeneousg roup of neurodegenerative diseases that are characterised by the accumulation of this protein. Called tauopathies, the most frequent is Alzheimer's disease (AD), which is immediately exceptional for the aggregation of as econd protein, amyloid b (Ab). The list of tauopathiesa lso contains Pick disease, progressive supranuclear palsy (PSP), corticobasal degeneration( CBD), argyrophilicg rain disease (AGD),G erstmann-Straussler-Scheinker disease, British dementia, Danish dementia, Guam Parkinsonism-dementia complex, tangle-only dementia, whitematter tauopathy with globularg lial inclusions, and frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP). [1] These pathologies are clinically diverse, ranging from progressive gait instability and gaze palsy,w hich is suggestive of PSP,t ot he loss of memory,w hich is associated with AD. [2] Ta ui samicrotubule-associated protein that is encoded by the MAPT gene on human chromosome1 7q21.31;i tp lays a role in the assembly and stabilisation of microtubules, which is essential for axonal transport. [3] Traditionally considered an intracellularp rotein, taui sa lso secreted in the cerebrospinal fluid (CSF), with increased levels in AD, in which it is used for confirmation of the clinical diagnosis. [4] Hyperphosphorylation at the paired helical filamente pitope 1( PHF1) at Ser396 and Ser404, as in AD,c auses ap athologicalc hange in conformation, [5] which leads to disassembly of the microtubuli and forms paired helical filaments (PHF) that aggregate furthert ill neurofibrillary tangles. [6, 7] Braak and Braak postulated the concept that tau spreads throughout the brain on the basis of AD postmortem anatomopathological investigations relatedt op rogress in phenotype, classified into VI stages. [8] The hypothesis of spreading was further corroboratedt hrough the demonstration that small tau fibrils transmitt oc onnected brain regions in transgenic mice, either wild-type tau-expressing animals after inoculation with brain extract from mutant P301S tau-expressing mice, [9] that is, mice overexpressing mutanth uman P301S tau after inoculationo fs ynthetic preformed fibrils (pff), [10] or following injection of pff in mice expressing mutant human P301L tau. [11] Frost et al. showed earlier that extracellulart au aggregates enter cultured cells and trigger intracellular tau to form fibrils that are competent to seed furthera ggregation, referringt os imilarities with Prion propagation. [12] As such, the finding of tau spreading between connecting brain regions is backed up by mechanismso ft ranscellular spreading on the microscale. This model, called prion-like, [1, 13, 14] is defineda s "the capacity of an assembled protein to induce the same abnormalc onformation in ap rotein of the same kind, initiating a self-amplifying cascade". [15] The two main components of this propagationa re, as such, conformational templating, exerted through "seeds" and transcellular spreading, implying spreading from one cell to another,t oc ontinuet he definitions used by Lewis and Dickson. [16] More arguments in favour of tau spreading have became available, including in vivo resultst hat human P301L tauknownt oc ause FTDP [17] -propagates independent of mRNA expression, that is, no mRNA is detected in cells accumulating tau, [18] and more recently throught he visualisation of tau on Ta u, am icrotubule-associated protein playing ak ey role in a group of neurodegeneratived iseases such as Alzheimer's disease, spreadst hroughout the brain, inducing pathology.A model akin to the spreading of prions has been raised owing to similar characteristics of inducing an abnormal protein conformationa samethodo fs elf-amplification, spreading protein aggregates over anatomically linked pathways. The search to identify the "seeds" that induce conformational change has received much attention;h owever, less is knowna bout the mechanisms by which tau is transmitted from cell to cell, socalled "transcellular spreading". In this review,w eg athere vidence regarding the spreading of tau throughout the brain and provide an overview of methods by which tauc an be released from neurons as well as taken up. Furthermore, we bring together mechanismso fn eurotoxicity behind tau spreading. Advancing our understanding about the spreading of tau can guide the search for therapeutic options for multiple neurodegenerative diseases aggregating tau.
positron-emission tomography( PET) imaging. [19] The tau spreading hypothesis is, however,s tilln ot entirely accepted, and the "selective neuronal vulnerability"t heory,w hich states that some cells are more vulnerable (e.g.,g enetic expression profiles)t ot he pathogenic processes initiating the disease, is an alternative explanation, [20] This is supported by the finding that neurons with long axons are especially affected. [21, 22] Having high-energyn eeds makes these neurons more prone to oxidative stress, which establishes differential vulnerability. [22] However,a sa forementioned, the affected neurons are anatomically connected, and therefore, the compatibility of both theories is not excluded.
In the adult humanbrain,asaresult of alternative RNA splicing of exons 2, 3a nd 10, six tau isoforms are expressed that range from 352 to 441 amino acids in length.I nclusion or not of the 31-amino-acid repeats equence encoded by exon 10 of MAPT divides the tau isoforms into two categories, both of which are expressed in similara mountsi nb rain tissue with four (4R) or three microtubule-binding repeats( 3R), respectively. [23] The 3R tau is physiologically the major foetal form, whereas the isoform with four tandemr epeatsi sa dult specific and also has higherm icrotubule polymerisation andb inding capacity than 3R tau. [23, 24] Neuronal inclusionsi nP ick's disease have 3R as the predominant tau isoform, [25] whereas filaments constituting mainly of 4R are indicative of PSP,C BD, or AGD. [26] [27] [28] Neuronal deposits in AD and tangle-only dementia (TD) contain both the 3R and 4R tauisoforms. [29, 30] The injection of brain homogenates of an umber of human tauopathies in wild-type mice induces tau inclusions resembling the respective source pathology, thereby also showcasing tau propagation in rodents. [31] Similar experiments in transgenic mice inoculated with immunopurified tau from stable human tau-expressing cell clones from differentt auopathies suggest that different diseases are associated with different sets of strains [32] described to spreadd ifferentially according to the disease of origin in experimentali njections of transgenic mice with CBD or AD brain extracts enriched in pathological tau. [33] Differential spreading,a sf or AD classified by Braak and Braak [8] and for AGD classifiedb yS aito et al., [34] is in line with distinguished neuropathological features, such as in PSP atrophy of the subthalamic nucleusa nd brainstem tegmentum with depigmentation of the substantia nigra, whereas in CBD, asymmetricf ocal cortical atrophy with depigmentation of the substantian igra is frequently found. [3] These taus trains, as known from Prion propagation theories, are ac oncept of unique "amyloid protein conformations". On the basis of biochemicala nd biological criteria,1 8d ifferent tau strains have been identified. [35] As such, the fibrillary structure dictates distinct cell pathology and progression rates and targets different brain regions,d etermining diversep athological phenotypes. [35] The differing structures of tau filaments originating from the brains of AD [36] and Pick's disease patients [37] were recently demonstrated by cryoelectron microscopy,w hich revealed different folding as ar esult of residues K254-F378 of 3R tau in Pick's tauf ilamentst hat is likely to explain the selectivei ncorporation of 3R tau in Pick bodies. [37] As such, conformers of assembled tau have been identified and have provided additional evidence for the claim that tau can have distinct folds in differentd iseases in the humanb rain. [37, 38] Unlike the conformationso ft au and its mode of aggregation, the spreading mechanisms of tau are rather unacknowledged. Endorsing its crucial role in pathophysiology,a no verview of the spreading of tau and the links inherently associated with the survival of tau and tau-mediated toxicity are provided in this review.
Synaptically Connected Spreading of Aggregates
The spreading of tau from the viewpoint of synaptic connectivity along with tau-induced synaptotoxicity is discussed first, and this is followed by examinationo ft he mechanism of the transcellular spreading.
Since the first in vivo evidenceo ft he trans-synapticp ropagation of human wild-type and P301Lt au was raised, [18, 39, 40] it has repeatedly been stated that synaptic connectivity,m ore than proximity,determines the pattern of spread. [41, 42] Early evidence was based on the time-dependent propagation of phosphorylated tau to brain areas known to be anatomically interconnected. [11] More recently,e xperiments with microfluidic devices, which rule out all mechanismso ft au transfer besides synaptic transmission, have demonstrated the vital role of synaptic connectivity. [22] Notably,a na lternative to trans-synaptic transmission, namely,m icroglia-mediated tau propagation, has also been suggested [43] (see below). Ta ut ransfers over synapses, and additional evidences uggests that tau exerts ap ossible pathologic role at pre-and postsynaptic terminals, which leads to the actual neurodegeneration. Postmortem analysisi nA Dp atients has shown the presence and symmetrical distribution of misfolded tau over pre-andp ostsynapses. [44] Recent findings demonstrate the ability of humanP 301L tau to spread trans-synaptically before the degeneration of axonalt erminals rather than throughl eakage. [45] Furthermore, Yoshiyama et al. have reportedh ippocampal synapse loss and impaired synaptic functioni na ddition to prominentm icroglial activation prior to tau aggregate formation. [46] Ta uh as its functiona ta xonal microtubuli, although control human brains also showt he presenceo ft au in dendritic spines. [47] Tauf rom pathological brainsd iffers;f or example, in AD, tau becomes hyperphosphorylated and misfolded. [47] Various authors have shown in vitro as well as in vivo that tau entry happens at somatodendritic compartmentsa sw ell as at the axonal terminals and movesb oth anterogradely and retrogradely between the axon and neuronal body [41, 48] (Figure 1 , number 7). Thus, tau transfers not only trans-synaptically but also transcellularly. [16] This retrograde transport of tau to the somatodendritic compartmentsd epends on hyperphosphorylation, [49] which allows tau to bypasst he microtubule-bindingbased diffusion barrier at the axonal initial segment. [50] Besides, retrograde transportation has also been shown fort au aggregates internalised at axonalt erminals. [48] ChemBioChem 2018, 19,2424 -2432 www.chembiochem.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim
Perisynaptic toxicityoftau
Postsynaptically,t au is essential for the dendritic localisation of Src kinase Fyn, [51] which in turn phosphorylates the N-methyld-aspartate( NMDA)r eceptor subunit 2( NR2). Consecutively, NR2 interacts with the postsynapticd ensity protein 95 (PSD-95), which leads to synaptic excitotoxic downstream signalling. [51] This complex, crucial for mediatingA b toxicity,b ridges tau and Ab neurotoxicity,a nd hence, dendritic targeting of Fyn is an attractive therapeutic approach for AD. [52] However,s ynaptic dysfunction does not only happent hrough pathways involvingt he NMDA receptor,a st he a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is also involved in tau-related impaired glutamate receptor trafficking and synaptic anchoring [49] ( Figure 1 , number 9). In addition to neurotoxicity related to glutamate receptors, muscarinic receptors also play ar ole. Dephosphorylated tau is very stable extracellularly,a nd the affinity of dephosphorylated tau to bind the M1 and M3 muscarinic receptors is nearly tenfold higher than that of acetylcholine;m oreover,u nlike acetylcholine, dephosphorylated tau does not induce desensitisationu pon repeated stimulation. [53, 54] Through the aforementioned characteristics, dephosphorylated tau induces an increase in intracellular calcium, which leads to cellular toxicitya sw ell as possible additional hyperphosphorylation and misfolding of tau [53] [54] [55] ( Figure 1 , number 13).
Presynaptically,t au has been shownt oi nterfere with normal synaptic functioning through binding of synaptic vesicles by its N-terminal domain, while stimulating vesicle crosslinking by actin polymerisation. As such, vesicle mobilisation is restricted, which reduces the release rate and lowers neurotransmission [56] ( Figure 1 , number 6). Whereas normalt au binds to vesicles, both mutantF TDP-17 tau (R406W,V 337M and P301L;0 N4R isoform)a nd hyperphosphorylated tau increase microtubular dissociation and enhance presynaptic localisation. [56] 
Transcellular Spreading of Tau
Cell-to-cells preading of tau can happen intercellularly through tunnelling nanotubes (TNTs) [57] or by release to extracellular space ands ubsequent cellular uptake. [58] The classificationo f structures differs from review to review,b ut here, ad ivision into releaseo ff ree extracellular tau versus vesicular transport seems logical (Figure 1 ). The first is theoretically possible through plasma-membrane translocation, secretory lysosomes and SNARE-mediatede xocytosis;h owever,c oncrete evidence has been obtained only for the latter. [59] Regarding vesicular transport, av ast body of literature on exosomes as as ecretion mechanism is available, and apart from that, ectosomes are also discussed.
The uptake of tau through fluid-phase endocytosis, particularly macropinocytosis, is discussed, and adsorptive endocytosis, an endocytotic process by which molecules are bound to the cell surfacea nd concentrated before internalisation, with the molecules interacting preferentially with generic complementaryb inding sites, such as lectin or charged interaction, is noted. [60] Further,t he different arguments in the clathrin-mediated endocytosis discussion are analysed and the uptake of intact exosomes is examined.
Intercellular spreading
TNTs, first described in 2004 by Rustom et al., [61] are filamentous actin-containing channels that bridger emote cells with diameters of 50-200 nm and ship proteins to whole organelles de facto intercellularly from neuron to neuron. As such, TNTs act as ideal transfer agents, as proposed in prion proteins, [62] and have been suggested to be at least partially accountable for tau spreading (Figure 1, mechanism 1 ). Experimentsb yT ardivel et al. show that soluble tau is ac onstitutive component of TNTs, together with f-actin,a nd also demonstrate that fibrillar human tau 1N4R is transferred from neuron to neuron through TNTs. [57] It is so far unknown whether the detected tau fibrils are cytosolict au or internalised in vesicles.F urthermore, exogenous tau fibrils favour the formation of TNTs. Another study confirms this and adds that tauf ibrils are able to enter cells, which suggestsself-enhancing propagation. [63] 
Release
The finding of monomeric tau in the CSF of AD patientsw ith early dementia onwards [64] leaves no doubt that tau is also present extracellularly,a ne ssential first step in the cell-to-cell transmission of tau apart from the TNTs. In wild-type mice, monomeric tau has also been identified in the brain interstitial fluid (ISF), which supports physiological cellular release of tau. [65] Further experiments have confirmed active releaseo f humant au in the absence of neuropathology [66] or cell death. [67] Finally,the identification of the exosomal transmission pathway has led Hall and Saman to the conclusion that tau is secreted and that the extracellulara ppearance of tau is not a result of neuronal death. [68, 69] Continuing,n euronal activity stimulates release of largely dephosphorylated tau. [70] Poolere tal. have demonstrated calcium-dependentt au release in vitro in healthy cortical neurons upon AMPAr eceptor activation,b ut not upon NMDA receptor activation,o nt he basis of presynaptic exocytosis and largely non-exosomal. These findings of presynaptic glutamate-release-induced tau release are supported by using in vivo microdialysis in wild-type mice. [71] Potassium-induced depolarisation also induces releaseo fb oth full-length and truncated tau from presynaptict erminals, and Sokolow et al. have shown that this release in postmortem AD synaptosomes is amplified relative to that in control tissue. [72] 
Mechanisms of release
The first possible extracellulara ppearance of tau is as free tau, which has been shown for both truncated free tau [73] and fulllength tau. [67] Immunoprecipitation of secreted, mainly truncated, dephosphorylated tau without any detergent also indicates that tau is not per se included in microvesicles or exosomes. [74] It is to be determined the extentt ow hiche xtracellular free tau plays ap hysiological role on intracellular calciumt hrough M1 and M3 muscarinic receptors [53] or is secreted because of intracellular abundance,w hich promotes pathological spreading. That assessment has therapeutic consequences in determining whether antibodies and anti-tauv accine approaches, recently reviewed by Braczynski et al., [75] should aim for intracellular tauorf ree extracellular tau.
Conventional protein secretion happens throughv esicular incorporation, passing the endoplasmic reticulum( ER) and Golgi apparatus, andr eleasing the protein content in SNAREmediated exocytosis. [59] Apart from that, there are unconventional pathways that consist of 1) direct plasma membrane crossingt ranslocation from the cytoplasm, 2) releaseb ys ecretory lysosomes, 3) microvesicle shedding and 4) exosome release. [76] Through the first two pathways, free protein is released, whereas through the latter two pathways, vesicles are released. An oncanonical pathway in which tau is driven out of the cell through SNARE-mediated exocytosis has been shown by Fontaine et al. [77] (Figure 1, mechanism 4) . The mechanism starts with the constitutivelye xpressed Heat shock cognate 70 (Hsc70), whichi nc ombination with DnaJ co-chaperones as a Hsc70-DnaJ complex and governs the triage of neurodegenerative proteins,i ncludingr efolding, disaggregation and protein degradation. [77] Thef inding is that overexpression of DnaJC5, a DnaJ known to promote exocytosis, induces extracellularr elease of wild-type, P301L andR 406W tau. [77] Thereby,s ynaptosomal-associated protein 23 (SNAP-23), au biquitously expressed SNARE protein involved in exocytosis, is engaged by DnaJC5. [77] As such, SNARE-mediated release of tau is linked with Hsc70-DnaJ-controlled proteostasis.
However,m any authors make note of unconventional secretion processes that are independent of the ER/Golgi-mediated secretory pathway,a ss ecretion can not be blockedb yc lassic protein secretion inhibitors such as brefeldinA(BFA) and monensin [67] or by BFA-induced disassembly of the Golgi complex [66] and is strengthened by lack of tau in the synaptic vesicle proteome. [78] Besides,d espite the fact that calcium homeostasisi s critical in tau release, calcium is not required. [66] Further,w hereas passivet ransport of proteins is unaffected by temperature change, heat-shock experiments in SH-SY5Y cells have revealed as ignificant increase in extracellular tau levels relative to cells incubated at 37 8C, which argues against passived iffusion. [66] Recently,t his unconventional secretionm echanism has been elucidated to happenf or full-length, soluble tau by direct plasma membrane translocation,w hich is favoured by tau hyperphosphorylation and mediated by sulfated proteoglycans [79] ( Figure 1, mechanism 5 ).
Extracellularv esicles (EVs) can transmitt au pathology,a nd the presence of phosphorylated tau inside EVs has been evinced. [80] Besides, tau release hasb een linked to Rab GTPases, which play ar ole in regulating intracellular vesicle trafficking and membrane fusion. Given that RAB7A gene expression and protein levels are upregulatedi nA Dp atients, Rab7A deletion decreases tau secretion; [81] as imilare ffect is observed upon Rab1a suppression, [82] which furthers upports the release of taut hroughv esicle transport.T wo common extracellular vesicles that are associatedw ith tau, both detectedi nt he mediumo fv ariousc ell lines under physiological conditions, [83] are ectosomes, also called microvesicles, whichs hed directly from the plasma membrane and are 100-1000 nm in diameter, and exosomes, which are 50-100 nm particles of endocytic origin [84] (Figure 1 , mechanisms 2a nd 3). Exosomes providea n acellularm ode of communication, as they transfer molecules intercellularly [85] and trans-synaptically,a nd presynaptic release and postsynapticu ptakeh ave been shown in Drosophila neuromuscularj unctions. [86] Exosomes form by the internalisation and trafficking of endosomes to multivesicular bodies (MVBs), which upon fusion with the plasma membrane resultsi nt he releaseofe xosomes. [87] The secretion of exosomes by cultured cortical neurons [88] and by differentiated neurons hasb een demonstrated;i ti s regulated by calcium and glutamatergica ctivity. [89] In tau overexpression experiments, phosphorylated tau hasb een shown to be associated with exosomes, [68, 90] on the basis of which Simóne tal. have theorised that vesiculart au secretion is ac ellular releasem echanism so as to eliminate any excess amount of tau protein. [90] However, in experiments at physiological tau levels,t au has not been detected in the exosome fraction, which argues against vesicular tau release and points at tau leakage as ar esult of cell death as an explanationf or the results obtained by both Saman et al. and Simóne tal. [67] Furthermore, secreted exosomes contain no detectable tau in SH-SY5Y neuroblastoma cells, which express endogenoush uman tau, [66, 91] and in primary cortical cultures. [88] Contrary,arecent study provides extensive evidencef or the secretion of both phosphorylated and dephosphorylated tau monomers and oligomers, as well as more complex aggregates, through exosomes by cultured neurons, N2a cells overexpressing human tau and in vivo in the human brain [22] ( Figure 2 ). Neuronal activity stimulates exosomal tau secretion, with tau confirmed to be within the exosomes;t he uptake of tau-containing exosomes has been shown by neurons and microglia, not astrocytes. [22] Furthermore, these exosomal tau seeds are capable of inducing aggregation of aggregate-prone 4R tau with DK280 mutation after being taken up by recipient cells. [80] Experimentsw ith microfluidic devices have demonstrated not only that exosomes can conduct neuron-to-neuron tau spreading but, moreover,t hat synaptic connections are required for exosomalt au transmission. [22] However,i nv ivo microglia are also at play in tau transmission, as they efficiently phagocytise tau ands ecretee xosomal tau upon ATPs timulation to the extent that tau propagation is drasticallyr educed by microglial depletion or by pharmacologic inhibition of microglial exosome synthesis. [43] In vivo, tau P301L transduction to neurons is more efficient in microglia-derived exosomes than in free tau. [43] Besides, relativelym ore tau is insoluble in exosomes than in N2a cells;t his suggestst he preferential release of tau aggregates through exosomes. Combined with the fact that the seedingefficiency is higher in exosome-associated tau aggregates than in free tau aggregates from broken exosomes,t hese results stress the importance of the exosomal pathway in tau spreading. [22] Ta ui sp resent in human CSF-derived exosomes [22] and in neuronally derived blood exosomes, which also show predictive value as biomarkers;the level of tau in human CSF-derived exosomes is significantly higher in AD patients compared to healthyc ontrol population. [92, 93] These neuronal exosomes derived from the plasma of patients with mild cognitive impairment (MCI) converting into AD seed phospho-tau pathology in normalm ice brains, contrary to MCI exosomes. [93] Thisb loodbased biomarker could be, if further developed, ag ood replacementf or the current existing CSF biomarkers (ratios of Ab42/total tau and Ab42/hyperphosphorylated tau), which require invasive sample collection.
As an explanation for the aforementioned resultst hat refute exosomal tau, Wang et al. mention the need fort he analysis of as ufficient amount of exosomes and the factt hat the tau content is cell-type dependent andd evelopmentally regulated. [22] Apart from exosomes, ectosomes are also found in the mediumo fb oth primary neuronal cell cultures and cultured E17 rat cortical neurons. [83] Under physiological conditions controlled for cell damage, tau has been shown to be secreted through vesicular pathways other than exosomes, namely,e ctosomes. Through NaCl washing, it has been confirmed that tau is inside the vesicles or anchored to the internal vesicle membrane. The releaseo ft his murine endogenous tau occurs for both the full-length form andt he C-or N-truncated form. As such, these in vitro and in vivo experiments have shown that endogenous tau is released through ectosomes in the absence of cell damage. On the basis of the fact that as ignificantly highera mount of tau is released throughe ctosomes than through endosomes, until the point of overaccumulation, it is theorised that release happens preferentially through ectosomesa nd that overaccumulation of tau leads to the macroautophagic pathway of proteolysis, whichc an be described as the formation of multivesicular bodies (MVBs) that either targetl ysosomes or are secreted as exosomes. [83] In an utshell, taut ransmission can take place trans-synaptically and transcellularly and either directly or with microglia as an intermediate step. Release happens as free tau through clathrin-mediated exocytosis as well as extracellularv esicles. These extracellularv esicles are defined as either exosomeso r ectosomes.
Tauu ptake
Similar to tau release, tau uptake can be divided into the uptake of free tau, either throughp assive transmembrane diffusion or active endocytosis, andt he uptake of tau incorporated in vesicles. Kinetically,t hree forms of endocytosis processes for uptake of free tau can be distinguished, namely,fluid-phase endocytosis (bulk uptake of solutes), adsorptive endocytosis (molecules bind to cell surfacea nd are concentrated before internalisation) and receptor-mediatede ndocytosis (specific ligand-receptor interaction). [60] However,t here is parallel structuring based on morphology that partially overlaps, namely, macropinocytosis (nonspecific), caveolar endocytosis, clathrinmediated endocytosis and clathrin-/caveole-independent endocytosis. [94] 
Taus pecies
Before going into the uptake mechanisms, we first address the specifications of the tau species that are taken up. Compared with microtubule-binding region (MTBR) tau monomer [= aminoa cids 243-375o ff ull-length (P10636-8) wild-type tau],F rost et al. described significant more uptake of tau aggregates in C17.2 cultured cells. [12] In line with these results,i t has been shown in human-induced pluripotent stem-cell 5) , similar to exosomalm arkers HSC70 and Alix, which indicates that tauisn ot peripherally attached to the exosomal membrane surface. B) ProteinaseK(Prot K) protection assay.Neuron-derived exosomes treatedwith or without 50 ng Prot Ki nt he presence or absence of 1% saponin (Sapo) for 5min or 1hat 37 8C, followed by western blot analysis. Note that tauisstrongly reduced (5 min) or even absent (1 h) in exosomes treated with bothProt Ka nd Sapocompared with treatment with Prot Ka lone, which indicates that the exosomal membraneprotects tau against Prot Kd igestion. Reproduced from ref. [116] .C opyright:2 017, Y. Wang et al. (hiPSC) experiments that tau oligomers based on recombinant human 2N4R tau, but not monomers, induce aggregation of pathological, hyperphosphorylated tau. [95] Upon measurement of recombinanta nd AD-derived tau aggregates based on tau repeat domain (RD;a mino acids 243-375) and in cultured HEK293cells and primary cultured neurons, the minimum tau assembly has been shown to be am inimum of three units (trimers). [96] In am ore recent study on av ariety of cell models, including human CNS-derived cell lines andi PS-derived neurons, full-length human tau (2N4R) is also internalised efficiently,h owever,f or both monomeric and oligomeric tau. [97] In another study,i tw as shown that tau fibrilsc ould not be taken up, which suggestst hat there is ar ange of lengths of the tau speciest hat are taken up by cells; [97] however,a dditional experiments are neededt oe lucidate the conflictingr esults regardingt he uptake or not of tau monomers.
Mechanisms of uptake
Early evidence of tau aggregate uptake by cells pointeda t fluid-phase endocytosis as the main mechanism of uptake [12, 48, 91] (Figure1,mechanism 8), in addition to adsorptive endocytosis, as shown for misfolded preformed tau fibrils. [98] Co-localisation with dextrana nd temperature dependency indicate an active process of endocytosis rather than passive transmembrane diffusion, whereas caveolin-mediated endocytosis can be excluded. [48, 99] Holmese tal. have specified this fluid-phase endocytosis as macropinocytosis, an actin-driven large invagination of the plasma membrane (0.5-10 mm)t hat internalises extracellular fluids [99] (Figure 1, mechanism 11 ). Extracellulart au RD fibrils stimulate their own internalisation by macropinocytosis, whichi sm ediated in vitro and in vivob y heparan sulfate proteoglycans(HSPGs) on the cell surface. [99] Significant clathrin-mediated endocytosis (CME) has been excluded by using Pit2B, [48] which is as mall-molecule inhibitor of clathrin terminal domain function, [100] and by using siRNA knockdown of clathrin heavy chain (CHC), [99] as in both experiments tau aggregate uptake continues. Inhibition of dynamin, ag uanosine triphosphatasei nvolvedi nt he fission reactiono f synaptic vesicle endocytosis, [101] by using Dynasore (80 mm)h as shown the endocytosis-dependentu ptake of low-molecularweight( LMW) tau species, which are oligomeric tau aggregates [48] (Figure 1, mechanism 10 ). This finding of the decreasedp ropagation of tau pathology upon inhibited dynamin activity has been confirmedf or TauP301L (1 mmD ynasore). [102] In as imilar experiment (80 mm Dynasore), Holmes et al. show that tau internalisation is not reduced, which leads to the conclusion that tau RD fibril uptake is independento fd ynamin 1. [99] Regardless of the contradictory results on dynamin dependency,i th as been shown that loss of Bin1, ap rotein that interacts with dynamin and negatively regulates endocytosis, promotes tau pathology. [102] This finding provides ap athophysiological mechanism for the fact that BIN1-amphiphysin2 is the second most prevalent genetic risk factor for late-onset Alzheimer'sdisease. [102] In terms of vesicular mechanisms, exosomes are also recruited to the cell cytosol. This in an intact manner,s urfing on filopodia,t ob es orted into endosomal trafficking circuits [103] ( Figure 1, mechanism 12 ). Exosomes might also make use of HSPGsf or internalisation. [104] In conclusion, cellular tau uptake happens through fluidphase endocytosis, with macropinocytosis in particular,a nd through adsorptivee ndocytosis. Clathrin-mediated endocytosis is still under discussion, though the involvement of BIN1i sevident. Both plasma membrane translocation and caveolin-mediated endocytosis have been experimentally excluded. Furthermore,u ptake of intact exosomes has been shown.
Intracellular sorting and survival
Ac rucial question in the whole tauopathy pathophysiology is what happens if tau becomes intracellular and what effect tau has on its host cell. Apart from the aforementioned synaptotoxicity,w ee laborate on intracellular sorting, survival and taumediated neurotoxicity.
Internalisation does not only happent rans-synaptically,a s Wu et al. have shownt he endocytosis of full-length LMW tau aggregates in axonala nd somatodendritic compartments, after which anterograde and retrograde trafficking takes place. [48] Ta ua ggregates, upon internalisation in endosomes, induce rupture of the vesicular membrane and, as such, provide aw ay for tau to escapet ot he cytoplasm, in which aggregate pathology can be further propagated. [102, 105] For internalised exosomes containing tau, escape from the lysosomal pathway with consequential release has also been shown. [22] Similar to pore-like amyloid structures formed by amyloid b and a-synuclein, tau has been reported to have the capacity to form annular protofibrils (APFs) that disrupt both plasma and organelle-membrane pore-forming protein toxins, which are a means to calcium influx and neurotoxicity. [106] Tauo ligomers,a s af irst step on the aggregation ladder,c an either proceed towards neurofibrillaryt angle formation through the formation of paired helical filaments (PHFs) that aggregate further or follow ad istinct pathway to arrange themselves in APF structures that are found in the brain tissue of patients with PSP and dementia with Lewy bodies( DLB). [106] Havingt au floating in the cytosol, one might wonder why tau is not degraded through the ubiquitin-proteasome system (UPS) knowing that phosphorylated tau is polyubiquitylated by CHIP,a nE 3u biquitin ligase that interacts directly with Hsp70/ 90. [107, 108] One answer lies in the acetylation of tau, which is one mechanism that prevents the ubiquitylationo fp hosphorylated tau andt hat is mediatedt hrough the histone acetyltransferase p300. [109] This acetylation of taui si ncreasedi nt auopathy patients through inhibition of p300a nd, hence,r educes acetylation-enhanced tau degradation. [109] Besides acetylation, tau phosphorylation at specific KXGS residues (S262/S356 sites), which are within the MTBR, [110] also prevents CHIP ubiquitylation. [111] On the other hand, class III protein deacetylase SIRT1 is involved in deacetylation, but it is downregulated in AD patients and not in MCI subjects, and SIRT1 inversely correlates with the amount of total insoluble tau as well as with other disease markers. [112] Furthermore, overexpression of the Hsp70 compound of the Hsp70/CHIP chaperone system reduces tau levels significantly in vivo, and this showcases the vital role of the selective eliminationo fa bnormal tau species. [107] With regard to the possible degradation escape pathways, a protein quality control (PQC) pathway,t ermed "misfolding-associated protein secretion" (MAPS), has recently been described, and it provides an explanation for the removal of defective proteins that have escaped degradation owing to proteasome insufficiency or dysfunction. Contraryt oc onventional PQC pathways that use degradation, MAPS is based on the secretion of misfolded proteins by using the ER-related deubiquitylase USP19.A lthough USP19 stimulates a-synuclein secretion, exosome-dependent tau secretion is not enhanced. [113] 
Alternative Spreading Mechanisms
Apart from the foregoing mechanismsf or transcellular spreading, we report af ew other less straightforward mechanismsf or tau spreading, and aside from the aforementioned microglial spreading, they presumably have limitedr oles in the pathogenesisoft auopathies.
In experimentsi nvolving the intraperitoneal injection of tau seeds resulting in intracerebral tauopathy,i th as been revealed that peripheral tau, similart op rions and Ab aggregates,c an reach the central nervouss ystem. As such, Clavaguera et al. have raised ah ypothesis of blood cellsa sc arrier of tau seeds, as is the case for amyloid seeds. However, it has to be noted that intraperitoneal administrationo ft he brainstem extracts of homozygous P301S tau transgenic mice is less effective than intracerebral injection, and tauopathy only developsi nh eterozygous mice transgenic for human mutant P301St au, not in wild-type mice. [114] In light of research on cellular ageing, it has been found in Escherichia coli that dividing cells segregate protein aggregates asymmetrically. [115] Although not yet specifically reported for tau itself, this accumulation through asymmetric segregation is at heoretic possibility.
Microglia might play an essential role in tau spreading, as depletion of microglia suppresses tau propagation and reduces excitability in the dentate gyrus in am ousem odel. [43] Furthermore, Asai et al. have raised the hypothesis that microglia might facilitatet au protein spreading between neuronsb y phagocytosing and exocytosing tau protein directly through exosomes or by phagocytosing neuronal axons containing tau to be secreted afterwards.
Conclusion
This review provides an overview of how tau spreadsa nd which pathologic effects it exerts. The variouss preading methods between neurons, either intracellularly, extracellularly or mediated through microglia, in addition to intracellular sorting, survival and neurotoxicity of tau on membranesa nd on preand postsynapse were discussed. Hence, we propose am odel in which diverse spreading methodsc ontribute to tau transmissiona nd effect toxicity. Neuronal death might alsoe levate extracellular tau, which reinforces neurodegeneration as microglia try and fail in ac leaning operation. Neuronal releaseoftau seems to be ac ombination of physiological function and tau bypassing safety mechanisms, such as retrograde transport throughp hosphorylation.
The diversity of symptomsa long the different neuropathies can be due to different propagation patterns throughout the brain. Upon looking back to the progress made in tauopathy research, we suggest that these macroscale variationsa re related to alternative transcellular spreading pathways, which leaves the option that each tauopathy has ad isease-specific composition of multiple spreading methods. Furthermore, the toxic effects of tau might differ along the neuron population; for example, muscarinic receptor relatedn eurotoxicity is likely more prevalent in cholinergic areas such as the entorhinal cortex.T oc ompletet he circle, the "selective neuronal vulnerability" theory could be the basis for the origin of pathologic tau seeds,w hich propagate throughout the brain alongt he prion-likem odel and exert their toxic effects on the involved neuronal networks, with all those complex interactions convergingt oas pecific tauopathy.A lthough we mention "converging", we nevertheless leavet he possibility that the tauopathies form am ultidimensional spectrum rather than individual pathologic entities.
